Pharmacoeconomic study of antipsychotic drugs in India

S. Nagaraja Prasad, Vedavathi H.


Background: Schizophrenia is a disorder of relatively high point prevalence, low incidence and high disability. It accounts for nearly 1.5-3% of total national expenditure on health care. There is a gross variation in the cost of various branded and generic versions of antipsychotics available in India. This can lead to decreased patient compliance. The present study was undertaken to highlight this variation in the cost of various preparations of antipsychotics (branded and generic) available in India.

Methods: Cost ratio and Percentage variation in cost of various antipsychotics available were calculated by standard formulae and analysed.

Results: There is a very high variation in the cost of various antipsychotics available in India. The highest variation in cost ratio was seen with risperidone 2mg, 3mg and olanzapine 10mg, while the highest percentage cost variation was seen with risperidone 3mg, 4mg, 1mg; olanzapine 2.5mg, 5mg, 50mg, 100mg; levosulpiride 25mg and chlorpromazine 20mg. The lowest percentage cost variation was seen with Flupenthixol 3mg and Amisulpiride 300mg.

Conclusions: There is a definite need to further strengthen the Drug Price Regulatory Mechanisms with regard to antipsychotics available in India in order to improve the patient compliance and thus cure rates of this burdensome and costly illness.


Anti-psychotics, Cost - analysis, Cost ratio, Pharmacoeconomics, Percentage cost variation

Full Text:



Sadock BJ, Sadock VA, Reiz P Ed. Kaplan and Sadock’s Comprehensive textbook of psychiatry. 9th ed. Wolter Kluwer, Lippincott Williams and Wilkins. 2009;1:1432-628.

Tsuang MJ, Tohen M, Jones PB. Textbook of psychiatric epidemiology 3rd ed. Wiley Blackwell, A John Wiley and sons; 2011:257-269.

Vyas JN, Ahuja N. Textbook of postgraduate psychiatry 2nd ed, Vol 1. Jaypee publications; 1999 reprint; 2008:150-187.

Knapp M, Mangalore R, Simon J. The global costs of schizophrenia. Schizophr Bull. 2004;30(2):279-93.

Kasper S, Papadimitriou GN Ed. Schizophrenia-Psychosocial approaches and current challenges. 2nd ed Informa UK ltd; 2009:362-276.

Rossler W, Salize HJ, Van Os J, Riecher-Rossler A. Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol. 2005;15(4):399-409.

India Brand Equity Foundation. Available at

Panchal SS, Pandit PR, Pathak AM, Lohi KM. Cost analysis of antiretroviral agents available in India. Int J Basic Clin Pharmacol. 2015:4:479-82.

Das SC, Mandal M, Mandal SC. A critical study on availability and price variation between different brands: impact on access to medicines. Indian J Pharm Sci. 2007;69(1):160-3.

Gazette of India-Extraordinary Part II-Sec 3(ii). Drug Price control Order, New Delhi. Ministry of Chemical and Fertilizers, Department of Pharmaceuticals (National Pharmaceutical Pricing Authority) 2013:2:36-67. Available at

National list of Essential medicines 2015. Available at 2015/Recommendations.pdf.

National Pharmaceutical Pricing Authority, Government of India. Available at 2013 pdf.

Ahuja J, Gupta M, Gupta AK, Kohli K. Pharmacoeconomics. Natl Med J India. 2004;17(2):80-3.

Cramer JA, Roy A, Burrell A, Fairchild CJ, Fuldeore MJ, Olendorf DA, et al. Medication compliance and persistence: Terminology and definitions. Value in Health. 2008;11:44-47.

Osterberg L, Blaschke T. Adherence to medication. N Eng J Med. 2005;353(5):487-97.

Piette JD, Beard A, Rosland AM, Mc Horney CA. Beliefs that influence cost related medication non-adherence among the ‘haves’ and “have nots” with chronic diseases. Patient Preference and Adherence. 2011;5:389-96.

Kardas P, Bishai WR. Compliance in infective medicine. Adv Stud Med. 2006;6(7):652-8.

Berki SE, Richards JW, Weeks HA. The mysteries of prescription pricing in retail pharmacies. Med Care. 1977;15(3):241-50.

Wertheimer AI, Grumer SK. Overview of international pharmacy pricing. Pharmacoeconomics. 1992;2(1):449-55.

The World Medicines Situation. World Health Organization 2011. Available at

Bate R, Jin GZ, Mathur A. Does price reveal poor quality drugs? Evidence from 17 countries. J Health Economics. 2011;30(6):1150-63.

Mohan S, Campbell N, Chokalingam D. Time to effectively address hypertension in India. Ind J Med Res. 2013;137:627-31.